Scientific Presentations

Xyzagen Scientific Presentations

Explore Xyzagen’s latest scientific presentations, where our experts share cutting-edge research, data, and insights with the global drug-development community.

Posters & Publications

Development and Clinical Modeling of Kv7 Channel Opener Prodrug for Treatment of Focal Onset Seizures, Status Epilepticus, and Functional Neurological Seizures

Authors: Sarah Thrasher, Polina Danshina, and Christopher Crean, Xyzagen Inc.

Development and Clinical Modeling of Kv7 Channel Opener Prodrug for Treatment of Neuropathic Pain

Authors: Christopher Crean, Sarah Thrasher, and Polina Danshina, Xyzagen Inc.

New Kv7 Channel Opener Chemistry for the Treatment of Seizures

Authors: Christopher Crean, Stevie Pope, Polina Danshina, Matthew Rich, David Fischler, Sarah Thrasher, and Angela Dixon, Xyzagen Inc.

Prodrugs of Kv7 Channel Opener Ezogabine Are Effective in Releasing Ezogabine and Blocking Seizures by Oral and Parenteral Routes of Administration

Authors: Christopher Crean1MS; Sarah Thrasher1 BS, Angela Dixon1 BS, Imani Susu1 BS, Edward Brown2 PhD, Polina Danshina1 PhD; 1- Xyzagen Inc., 2-Expert Chemistry Services

CPL-01, A Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Systemic Exposures

Authors: Pope, Stevie1; Crean, Christopher1; Thrasher, Sarah1; Chen, PJ2; Chen, Lee2; Hu, DeeDee3; Onel, Erol2
1 Xyzagen, Inc., Pittsboro, NC; 2 Cali Biosciences, US, LLC, San Diego, CA; 3 St . David’s Medical Center, Austin, TX

SPR-397, 0.25% Ophthalmic Solution May Break the Inflammatory Cycle of Dry Eye Disease

Christopher Crean, MS1, Angela Dixon1, Wendy Cousin, Ph.D.2, Ransi Somaratne, MD, FACC2
1. Xyzagen, NC, United States. 2. Spring Discovery, CA, United States